Regulations
FDA 483 for Catalent behind CRL for Regeneron
RegulationsFDA 483 for Catalent behind CRL for RegeneronFDA 483 for Catalent behind CRL for Regeneron
The 483 at the Indiana site resulted in three observations and is believed to be the cause of the rejection of Regeneron’s aflibercept 8 mg.